Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR‐TKIs Resistance

Abstract

ABSTRACT Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are the standard treatment choice for advanced non‐small cell lung cancer (NSCLC) patients with EGFR mutations. EGFR‐TKIs have made significant progress in the treatment of advanced NSCLC patients, but drug resistance issues still inevitably arise. The mechanism of drug resistance and subsequent treatment has been current research challenge and priority. Immune checkpoint inhibitors (ICIs) are a new choice for late‐stage NSCLC patients without druggable molecular alterations. Currently, several studies have applied ICIs therapy for NSCLC patients with EGFR‐TKIs resistance and explored the potential efficacy of ICIs. This review elaborates on the current status of immunotherapy after EGFR‐TKIs resistance, including ICIs monotherapy, combined with EGFR‐TKIs, chemotherapy, antiangiogenic drugs, and other therapies.

Keywords

• EGFR‐TKIs resistance
• epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI)
• immune checkpoint inhibitors
• immunotherapy
• non‐small cell lung cancer (NSCLC)